News

As specialty drug launches grow, pharma leaders are rethinking patient access as a core commercialization strategy to reduce delays and improve therapy starts.

By prioritizing solutions such as reusable plastic pallets, pharmaceutical companies can ensure that their high-value innovations are protected by equally innovative packaging.

In this week's Pharma Pulse, House committees advance key legislation targeting PBM kickbacks and pharmacy access, Macfarlane Packaging partners with eutecma to bring modular cold chain solutions to the UK, and more.

Intelliguard and Accucold have launched an RFID-enabled refrigerated cabinet to improve hospital medication tracking, visibility, and cold-chain control.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

The US DSCSA requires digital drug traceability to ensure patient safety, but supply chains face data errors; deploying AI adds an intelligent compliance layer to automate process tracking and protect drug access.

Pharma supply chains are embracing AI, digital twins, IoT, and DSCSA-driven traceability to improve resilience, visibility, and profitability amid rising global disruptions.

Kieran Daly discusses how adherence programs can improve patient outcomes, support specialty pharmacy performance, and reduce healthcare costs.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

In this week's Pharma Pulse, the Trump administration expands TrumpRx to over 600 generics, the Supreme Court clears the way for long-term Medicare drug price negotiations, Eli Lilly moves deeper into genetic medicines with a $202 million acquisition, and the FDA loses more top leadership.

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

Rahul Mittal explains how execution infrastructure can help generics manufacturers improve hospital access, reduce delays, and strengthen coordination.

The expansion of TrumpRx will increase price transparency and purchase options of generic drugs for cash-paying patients.

There is never a quiet moment to step into a new role, and joining Pharmaceutical Commerce as editor has been no exception.

The industry is asking harder questions about how therapies reach people, who can afford them, and what it will take to close the gaps that remain.

The Supreme Court declined pharma appeals, letting Medicare drug price negotiations under the IRA proceed, solidifying federal pricing authority.

Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.

Ben Sharples, LogiPharma event director, examines how life sciences organizations are adapting to AI in the supply chain, with expert testimony from LogiPharma partners.

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares.

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes.

In today’s Pharma Pulse, FDA leadership changes with Makary’s resignation, Lilly shares new Zepbound and GLP-1 data, and new study data on prior authorization reform outlook.

US pharma supply chains are shifting amid regulation and geopolitics, with BIOSECURE driving less Asia reliance and more complex, distributed networks.

Will Shrank, MD, explains the main hurdles to specialty therapy access, and what will impact the market over the next few years.

Jessica Lovett explains the importance of being connected to the broader access ecosystem and how leveraging partnerships that can provide global insight and intelligence.

FDA commissioner Marty Makary is planning to resign today, according to sources close to the White House.

Tommy Bramley breaks down the benefits of incorporating real world evidence and data early into a product's lifecycle.